Hello Iris! You should read this article. It really brought out some memories that I had filed away. Seems like Peg IFN continues to slay some Dragons, with similar experiences. It has been 11 years SVR for me, but those times feel like yesterday. Here’s a small clip:
"Indeed, peginterferon [PegIFNα] use in the United States is very uncommon, and the results of this trial are unlikely to change practice patterns," she pointed out, though she noted that practice patterns may differ in other regions of the world where chronic HDV is more prevalent.
"The benefit of PegIFNα when combined with bulevirtide appears to be in achieving a higher response during treatment and less in reducing the incidence of virologic relapse among patients with a response," Terrault explained. Side effects of PegIFNα are common and sometimes serious, she added, and can include mood disturbances, cytopenias, and hepatitis flares.
Bulevirtide monotherapy has been associated with a high incidence of virologic relapse after treatment discontinuation, she wrote, suggesting that long-term treatment may be needed -- "a prospect made less palatable by the requirement for daily subcutaneous injections."
Iris Dragonfly said
Jun 10, 2024
omg, without actually reading the text does this mean hep D is strong/worse than hep C and it need the Peg for a boost?
I'll come back and read it soon but there is Sooooooooooooooooooooooo much on my plate rite now.
Love you all!
Iris
Hello Iris! You should read this article. It really brought out some memories that I had filed away. Seems like Peg IFN continues to slay some Dragons, with similar experiences. It has been 11 years SVR for me, but those times feel like yesterday. Here’s a small clip:
"Indeed, peginterferon [PegIFNα] use in the United States is very uncommon, and the results of this trial are unlikely to change practice patterns," she pointed out, though she noted that practice patterns may differ in other regions of the world where chronic HDV is more prevalent.
"The benefit of PegIFNα when combined with bulevirtide appears to be in achieving a higher response during treatment and less in reducing the incidence of virologic relapse among patients with a response," Terrault explained. Side effects of PegIFNα are common and sometimes serious, she added, and can include mood disturbances, cytopenias, and hepatitis flares.
Bulevirtide monotherapy has been associated with a high incidence of virologic relapse after treatment discontinuation, she wrote, suggesting that long-term treatment may be needed -- "a prospect made less palatable by the requirement for daily subcutaneous injections."
I'll come back and read it soon but there is Sooooooooooooooooooooooo much on my plate rite now.
Love you all!
Iris
Hepatitis D Regimen
Peg Interferon is back as part of the Hep D regimen. We can relate…